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RT-PCRAbstract Background: MDR continues to be a major challenge to effective chemotherapeutic
interventions against cancer. Defining major factor contributing to MDR and inhibiting their
action may thus be used for reversing MDR.
Aim: This work aimed to evaluate the role played by MRP-1 and GST-Pi in MDR, and to explore
the possible role of indomethacin as an inhibitor of chemotherapy resistance in patients with AML.
Subjects and methods: The study included 2 groups, one included 20 healthy volunteers and the sec-
ond included 50 AML patients. All patients received one cycle of standard induction chemotherapy,
then regrouped according to their response to either CR group or unremitted group. Unremitted
patients received a second cycle of chemotherapy combined with indomethacin. From each subject
a blood sample was drawn before and after the 1st cycle of chemotherapy and after the 2nd cycle.
From blood, mononuclear cells were separated, mRNA was extracted, and RT-PCR was carried
out to detect GST-Pi and MRP-1 gene expression.
Results: GST-Pi expression in CR group was 60% before therapy that significantly decreased to
30% after therapy. While in unremitted group, its expression significantly increased from 30%
before to 80% after therapy. GST-Pi positive patients had a significantly lower overall and disease
free survival time than GST-Pi negative patients (P = 0.000 and 0.039, respectively). While MRP-1
expression was so low (20%) and remained unchanged after therapy in both groups. MRP-1 expres-
sion did not affect overall or disease free survival. Taking indomethacin with 2nd cycle of
chemotherapy in unremitted patients resulted in a significant inhibition of GST-Pi expression
and a significantly longer overall survival time than those taking 2nd cycle chemotherapy alone
(P = 0.034).SAIDs,
al; OS,
252 S.A. Ebeed et al.Conclusion: MRP-1 is not likely to contribute to MDR, while GST-Pi might have a role in MDR
phenotype in AML patients. Furthermore, GST-Pi inhibition significantly reduced MDR in AML
patients.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multidrug resistance (MDR) is a prime problem restricting the
success of chemotherapy in patients with a variety of hemato-
logical and solid malignancies. MDR can be defined as the
cross-resistance of cancer cells to a number of structurally or
functionally unrelated anticancer drugs. Tumors are composed
of heterogeneous populations of malignant cells. Some popula-
tions are chemo-sensitive while the remaining are chemo-
resistant. Chemotherapy kills sensitive cells, leaving a high
proportion of resistant cells that would begin to grow again,
and chemotherapy may fail.1
Various mechanisms were proposed that underlie MDR in
malignant cells. One mechanism, involves molecular pumps
present in membranes of tumor cells that actively eject drugs
from the cell, which allows tumor cells to avoid the toxic
effects of the drug. The pump that was found responsible for
MDR in acute myeloid leukemia (AML) is the multidrug resis-
tance–associated protein-1 (MRP-1). MRP1 is an ATP-
binding cassette transporter protein which was identified as
the gene that confers MDR in lung cancer cells. MRP1 acts
in order to protect certain tissues from xenobiotics by mediat-
ing the efflux of many organic anions, including glutathione
conjugates. MRP1 participates in cellular efflux of reduced
and oxidized forms of glutathione and thus contributes to
the many physiological and pathophysiological processes influ-
encing glutathiones, especially oxidative stress.2
Another important mechanism of MDR in cancer cells is by
increasing cell detoxifying enzymes in tumor cells, most impor-
tantly Glutathione-S-Transferase-Pi (GST-Pi).3 GST-Pi is a
cytosolic phase II detoxification enzyme that promotes the
conjugation of glutathione to an electrophilic center of endoge-
nous and exogenous compounds, resulting in glutathione-
conjugates formation. GST-Pi is thought to participate in the
development of drug resistance in two ways, the first via direct
detoxification of chemotherapy agents. The second, through
direct glutathionylation of critical signaling molecules that
may serve as a trigger for cellular events that are influenced
by oxidative stress. More specifically, GST-Pi inhibits the
MAPK pathway that promotes cell survival in response to
oxidative stress.4
Since its discovery, overcoming MDR has been a major
concern in cancer therapy. This is most effectively achieved
through inhibiting the action of key role players in the molec-
ular mechanisms underlying MDR, thus reversing MDR.5
Thus inhibiting MRP-1 and/or GST-Pi is expected to reverse
MDR in patients expressing either of them. Indomethacin,
1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid,
is a non-steroidal anti-inflammatory drug that displays anti-
inflammatory, analgesic, and antipyretic properties. It acts
by non-selectively inhibiting both cyclooxygenase (COX)-1and COX-2.6 Studies have suggested that indomethacin can
modulate both GST-Pi and MRP-1, as it is a potent non-
competitive inhibitor of GST-Pi,7 and by inhibiting the
MRP-1 promoter activity, it inhibits MRP-1.8
This work aimed to evaluate the role of MRP-1 and GST-Pi
in multidrug resistance in AML patients, and to explore the
possible role of indomethacin as an MDR inhibitor in leuke-
mic patients.2. Subjects and methods
2.1. Subjects
The study included 70 subjects assigned to 2 groups: group 1,
Included 20 healthy volunteers (8 males and 12 females) clini-
cally free from any disease, their mean age was 42.40 ± 4.47 y,
and group 2, Included 50 patients with AML (26 males and 24
females), of matched age (47.72 ± 2.46 y) as group 1. Patients
were recruited from the Haematology Department, Medical
Research Institute, Alexandria University; during the period
from March 2006 till December 2008. The study has been
approved by the local ethics committee, and subjects enrolled
in the study provided an informed consent each.
2.2. Methods
To all patients the following was done: full history recording,
thorough clinical examination, routine laboratory investiga-
tions including complete blood picture, liver and kidney func-
tions, Radiological investigations including chest X-ray,
abdominal ultrasound and ECG, and bone marrow examina-
tion including morphological and cytochemical confirmation
for FAB classification.
Exclusion criteria included preceding clonal hematological
diseases, previous chemo- or radiotherapy for solid tumors,
abnormal kidney and liver functions, clinical or ECG signs
of heart failure.
All patients received one cycle of standard induction
chemotherapy, consisting of daunorubicin 45 mg/m2 daily on
days 1–3 and cytarabine arabinoside 200 mg/m2 daily on days
1–7 (3 + 7). Ten patients died during the induction cycle, and
the remaining 40 patients were evaluated after receiving the
induction cycle to determine whether they achieved complete
remission (CR) or not. Twenty patients were considered to
be in CR group as they met the established criteria, including
blast cells <5%, platelets count P100  109/l and no evidence
of leukemia at other sites observed within six months. The
unremitted (UR) group included 20 patients with blast cells
>5%, or evidence of leukemia at other sites. The UR group,
including patients showing no response to treatment, received
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cin (50 mg/8 h daily on days 1–7).
2.2.1. Blood sampling
A five ml venous blood sample was collected from each control
subject, and patient (at presentation, after the 1st cycle of
chemotherapy and after the 2nd cycle combined with indo-
methacin). Blood samples were collected into EDTA coated
tubes and were processed using gradient centrifugation by
Ficol-Paque Plus (Biochrom AG, Berlin, Germany) to obtain
the buffy layer. Cells were washed by PBS twice, pelleted
and then stored at -80 C until they were used.
2.2.2. RNA extraction
Total RNA was extracted from patients’ samples using the
SV Total RNA Isolation System (Promega Corporation,
Madison, USA). According to the manufacturer’s instruc-
tions, cells were thawed in lysis buffer, diluted and cen-
trifuged at 12,000–14,000g for 10 min to remove cell debris.
RNA was precipitated from the cleared lysate by 95% etha-
nol then separated through spin columns. RNA was washed
and treated by DNase and washed again before elution by
100 ll of nuclease-free water.
The concentration of the extracted RNA was assessed by
the NanoDrop ND-1000 UV–Vis Spectrophotometer that
measures the optical density at 230, 260 and 280 nm. All sam-
ples included in the study had A260/A280 ratio ranging from 1.7
to 2.1.
2.2.3. RT-PCR for MRP-1 and GST-Pi
Reverse transcription was done by Reverse Transcription Sys-
tem (Promega, Madison, USA). The kit used AMV Reverse
Transcriptase and oligo (dT)15 primer to synthesize single-
stranded cDNA from total RNA.
PCR was carried out using Go Taq Green Master Mix
(Promega Corporation, Madison, USA). Each PCR mixture
consisted of 25 ll PCR master mix; 1 ll of each amplification
primer (100 pmol/ll) and 1 lg cDNA and the volume wasFigure 1 Gel electrophoresis of PCR products. Lanes 1–4 show the
GST-Pi and the 100 bp band of b-actin.brought to 50 ll by adding deionized water. The primers used
for the amplifications are as follows:4
MRP-117 bp banF-50-GGTCACGCACAGCATG and
R-50-GTACACGGAAAGCTTGAC produce a 417 bp
fragment,GST-Pi F-50-GGCTCACTAAAAGCCTCCTG and
R-50-CTACTGATACACTTCCGTGA produce a
244 bp fragment,b-actin (house-keeping gene): F-50-GCACCACACCTTCTA
CAATGA and
R-50-GTCATCTTCTCGCGGTTGGC produce a
100 bp fragment.Thermal cycling started by a first denaturation step of 5 min at
94 C, followed by 40 cycles of 95 C for 60 s, 52 C for 60 s
and 72 C for 90 s and a final extension for 10 min at 72 C.
PCR products were separated by electrophoresis on 2% agar-
ose gel, then they were stained by ethidium bromide and finally
visualized by UV Fig. 1.2.3. Statistical analysis
Statistical analysis was performed using the SPSS (Statistical
Package for the Social Sciences) software version 18.0 (SPSS
Inc., Chicago, IL, USA).
MRP-1 and GST-Pi expression was converted to dichoto-
mous variable either negative or positive by combining the sev-
eral grades of positivity into positive. For variables’
description, the percent was used for qualitative variables
and the mean with the standard deviation for quantitative nor-
mally distributed variables. The relative risk was used to assess
the risk among those who are parameter positive relative to
those who are parameter negative. Kaplan–Meier survival
curves were used to demonstrate disease free and overall sur-
viving through the follow-up duration, using the mean survival
time and its 95% confidence interval as descriptive for thed of MRP-1, while lanes 5–8 show the 244 bp band of
Table 1 Mean ± standard error (M ± SE) of all hematological parameters in control group, AML patients, complete remission











Controls (n= 20) 5.59 ± 0.33 0.0 ± 0.0 250.3 ± 11.3 4.38 ± 0.11 12.02 ± 0.27
AML patients (n= 50) 32.15 ± 6.29 55.20 ± 5.20 107.6 ± 17.1 2.98 ± 0.16 8.57 ± 0.45
CR group (n= 20) At presentation 33.44 ± 12.12 62.6 ± 7.7 129.1 ± 33.0 3.01 ± 0.25 8.74 ± 0.72
After 1st cycle 4.6 ± 0.7^ 0.9 ± 0.48^ 118.7 ± 13.5* 3.41 ± 0.22* 9.68 ± 0.68*
UR group (n = 20) At presentation 23.03 ± 7.29 44.40 ± 7.44 108.7 ± 25.9 3.02 ± 0.24 8.76 ± 0.52
At relapse 30.53 ± 11.69*,h 52.70 ± 9.75* 85.1 ± 24.2* 2.89 ± 0.21* 8.36 ± 0.52*
After 2nd cycle + indomethacin 5.74 ± 2.19h 1.5 ± 1.5#,h 128.3 ± 24.1* 3.25 ± 0.09* 8.66 ± 0.37*
Student’s t-test, significant when P < 0.05.
* Significant when comparing with control group.
^ Significant when comparing mean values at presentation with corresponding values after 1st cycle of chemotherapy in CR group.
# Significant when comparing mean values after induction cycle and after 2nd cycle + indomethacin with corresponding values at presen-
tation in UR group.
h Significant when comparing mean values after 2nd cycle + indomethacin with corresponding mean values after induction cycle in UR
group.
254 S.A. Ebeed et al.different survival times. Comparisons between the different
survival distributions were done using the log rank test. All
tests were 2 sided and alpha was set at 0.05.3. Results
The study included 50 AML patients and 20 healthy individu-
als as a control group. After the first cycle of chemotherapy
AML patients were divided into two groups, CR group
(n = 20) and UR group (n= 20), the latter was treated with
a 2nd cycle plus indomethacin. Ten patients died during the
induction cycle of chemotherapy.
3.1. Hematological results
Mean ± standard error (S.E.) of all hematological parameters
in control group, AML patients, complete remission group
and UR group are presented in Table 1.
WBCs count and the blast cells percent followed the same
pattern. The mean values of WBCs count and blast cells per-
cent in AML patients were significantly higher than those in
control group (32.15 ± 6.29 vs 5.59 ± 0.33  109/l and
55.20 ± 5.20 vs 0.0 ± 0.0; respectively). In CR group, at pre-
sentation they were significantly higher than in control group
(33.44 ± 12.12  109/l and 62.6 ± 7.7; respectively), and sig-
nificantly decreased after the 1st cycle of chemotherapy to
the normal control level (4.6 ± 0.7  109/l and 0.9 ± 0.48;
respectively), while in UR group, levels at presentation and
after induction therapy were significantly higher than the con-
trol group and not significantly different from each other
(23.03 ± 7.29 and 30.53 ± 11.69  109/l and 44.40 ± 7.44
and 52.70 ± 9.75; respectively). After the 2nd cycle of
chemotherapy combined with indomethacin, WBCs and blast
cells percent levels significantly decreased and became within
the control level (5.74 ± 2.19  109/l and 1.5 ± 1.5;
respectively).
The mean value of platelets count in patients with AML
was significantly lower than that in control group (107.6
± 17.1 vs 250.3 ± 11.3  109/l; respectively). In CR group atpresentation and after the 1st cycle of chemotherapy mean
values were significantly lower than those in the control group
and not significantly different from each other (129.1 ± 33.0
and 118.7 ± 13.5  109/l; respectively). While in UR group,
at presentation, at relapse and after the second cycle of
chemotherapy combined with indomethacin mean levels were
significantly lower than in control group and showed insignif-
icant variations (108.7 ± 25.9, 85.1 ± 24.2 and 128.3
± 24.1  109/l; respectively).
The mean values of RBCs count and hemoglobin concen-
tration followed the same pattern. In patients with AML, they
were significantly lower than in control group (2.98 ± 0.16 vs
4.38 ± 0.11  106/l and 8.57 ± 0.45 vs 12.02 ± 0.27 g/dl). In
CR group, mean levels at presentation and after the 1st cycle
of chemotherapy were nearly within the same range and were
significantly lower than in control group (3.01 ± 0.25 and
3.41 ± 0.22  106/l and 8.74 ± 0.72 9.68 ± 0.68 g/dl; respec-
tively). Also in UR group, the mean values at presentation,
after induction cycle and after the 2nd cycle of chemotherapy
combined with indomethacin showed insignificant variations
and were significantly lower than in control group (3.02
± 0.24, 2.89 ± 0.21 and 3.25 ± 0.09  106/l and 8.76 ± 0.52
8.36 ± 0.52 and 8.66 ± 0.37 g/dl; respectively).
3.2. GST-Pi expression in patients with AML
Number and percent of AML patients with positive GST-Pi
and MRP-1 expression and comparisons of studied groups
and subgroups are represented in Table 2. Half the control
group subjects and 52% of AML patients had positive GST-
Pi expression, with no significant difference between the two
groups.
In CR group, at presentation 60% of patients were positive
for GST-Pi, which decreased to 30% after the 1st cycle of
chemotherapy. Neither percent was significantly different from
the control group, but they were significantly different from
one another. In UR group, at presentation 30% of patients
expressed GST-Pi which was not significantly different from
the control percent, while after induction cycle, the percent
positivity increased to 80%, which was significantly higher
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indomethacin, the percent of patients with positive GST-Pi
expression decreased to 20%, which was significantly lower
than at relapse and control percent.
The percent of GST-Pi expression positivity after the 1st
cycle of chemotherapy in CR group was significantly lower
than the percentage after induction cycle in the UR group.
3.3. MRP-1 expression in patients with AML
In the control group, 20% of subjects had positive MRP-1
expression, while in AML patients only 12% were positive
for MRP-1, with no significant difference between the two
groups. In CR group, at presentation 20% of patients were
positive for MRP-1, which decreased to 10% after the 1st cycle
of chemotherapy. In UR group, at presentation and after
induction cycle, only 10% of patients expressed MRP-1 while
after the 2nd cycle combined with indomethacin, none of the
patients was positive for MRP-1 expression. None of the per-
cents was significantly different from the control group or
from one another.
Fig. 2 represents the percent positivity of both GST-Pi and
MRP-1 in the two groups through all study points.
3.4. Disease free survival (DFS)
Fig. 3a represents the Kaplan–Meier DFS curve of AML
patients classified according to GST-Pi expression. Patients
with positive GST-Pi expression had shorter mean DFS time




AML patients (n= 50)
CR group (n= 20) At presentation
After 1st cycle
UR group (n= 20) At presentation
At relapse
After 2nd cycle + indomethacin
Cochran’s Q test, significant when P 6 0.05.
* P1: significant when comparing with control group.
^ P2: significant when comparing values at presentation with correspon
# P3: significant when comparing values after induction cycle and after
in UR group.
h P4: significant when comparing values after 2nd cycle + indomethaci
r P5: significant when comparing values after the 1st cycle of chemothe(28.56 months). The difference was statistically significant
(P= 0.039), with a log-rank value of 4.23.
Fig. 3b represents the DSF curve of AML patients accord-
ing to MRP-1 expression. There was no significant difference
(P= 0.548) in mean DFS time between patients with
positive (25.00 months) and negative (20.35 months) MRP-1
expression.
3.5. Overall survival (OS)
Fig. 3c represents OS curve of AML patients according to
GST-Pi expression. Patients with positive GST-Pi expression
had shorter mean OS time (15 months) than patients with neg-
ative GST-Pi expression (34.50 months). The difference was
statistically significant (P= 0.007), with a log-rank value of
7.25.
Fig. 3d represents OS curve of AML patients according to
MRP-1 expression. There was no significant difference
(P= 0.634) in mean OS time between patients with positive
(27.33 months) and negative (24.41 months)MRP-1 expression.
3.6. Survival when combining indomethacin with chemotherapy
Fig. 4 represents the OS curve of patients treated by
chemotherapy alone and patients treated by chemotherapy
with indomethacin. Patients taking chemotherapy in combina-
tion with indomethacin had longer mean OS time (31 months)
than patients taking chemotherapy alone (18.87 months). The
difference was statistically significant (P = 0.034), with a log-
rank value of 4.45.T-Pi and MRP-1 expression and comparisons of groups and
GST-Pi expression MRP-1 expression
+ve/total % +ve/total %
10/20 50 4/20 20
25/50 50 6/50 12
12/20 60 4/20 20
6/20 30^ 2/20 10
P2 = 0.020
6/20 30 2/20 10




4/20 20*,h 0/20 0
P1 = 0.016
P4 = 0.000
ding values after 1st cycle of chemotherapy in CR group.
2nd cycle + indomethacin with corresponding values at presentation
n with corresponding values after induction cycle in UR group.
rapy in CR group with that after induction cycle in UR group.
Figure 2 The percent positivity of both GST-Pi and MRP-1 in CR and UR groups through all study points.
Figure 3 Disease free survival according to (a) GST-Pi and (b) MRP-1 expression and overall survival according to (c) GST-Pi and
(d) MRP-1 expression in AML patients.
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As presented in Table 3, in CRgroup there was a significant pos-
itive correlation between GST-Pi expression and both WBCs
count and blast cells % at presentation (r= 0.583, 0.612 and
P = 0.038, 0.030; respectively), while in UR group, GST-Pi
expression was significantly correlated with WBCs count and
blast cells % after induction cycle (r= 0.612, 0.667 andP = 0.030, 0.018; respectively) and after 2nd cycle +
indomethacin (r = 0.667, 0.667 and P = 0.018, 0.018;
respectively).
As for MRP-1 expression, there was a significant positive
correlation between MRP-1 expression and WBCs count in
CR group at presentation (r = 0.612 and P = 0.030). There
was no significant correlation between GST-Pi or MRP-1
and any of the other parameters in all studied groups.
Figure 4 Overall survival according to chemotherapy with and
without indomethacin in all patients with AML.
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MDR continues to be a central problem in treatment with
chemotherapy, especially in leukemia. New drugs and treat-
ment protocols have enhanced disease prognosis among
AML patients; nevertheless, initially responsive tumors ulti-
mately relapse and develop resistance to drugs. Treatment of
resistant leukemic cells is usually very difficult because the
range of resistance generally extends even to drugs to which
leukemic cells have never been exposed.9
4.1. Expression of GST-Pi and MRP-1 with MDR
There are five different classes of GSTs in human cells that act
as determinants for response to chemical insult.10 GST-Pi
isoenzyme inactivates chemotherapeutic drugs by conjugating
them to glutathione. The involvement of GST-Pi in chemo-
resistance is established for cultured cancer cell lines, but its
role in vivo is still unclear. Increased GST-Pi expression
detected as strong immunoreactivity has been documented to
contribute to chemotherapy resistance in AML patients.11
Our results showed that no significant difference in percent
positivity of GST-Pi expression existed between treatment
naı̈ve AML patients and controls (52% and 50%; respec-
tively), which indicates that GST-Pi is innately expressed in
peripheral mononuclear cells. Our results were in agreement
with those of Lohri et al.12 who observed that mRNA levelsTable 3 Correlation of GST-Pi and MRP-1 with laboratory param
GST-Pi CR group (n= 20) At presentation
UR group (n = 20) After induction cycle
After 2nd cycle + indome
MRP-1 CR group (n= 20) At presentation
p: Statistical significance (correlation is significant at P 6 0.05).
r: Pearson’s two-tailed correlation coefficient.of GST-Pi were equally expressed in healthy donors and in
AML patients.
After the first cycle of chemotherapy, the percentage of
GST-Pi expression in CR group significantly decreased from
60% before treatment to 30% after achieving CR; on the other
hand, in UR group, it significantly increased from 30% at pre-
sentation to 80% after induction cycle. In addition, GST-Pi
expression was found to be correlated to WBCs count and
% blast cells at presentation in both CR and UR groups.
Our results confirmed the finding of other studies that GST-
Pi RNA levels in treated AML patients remained the same
or fell after chemotherapy in responding patients, indicating
that GST-Pi expression is not induced by chemotherapy in
responding patients.13,14 In UR group, treatment may have
induced rapid apoptosis of the sensitive cell fraction leaving
resistant cells. Thus up regulation of GST-Pi expression after
induction cycle is most probably due to clonal selection of leu-
kemic cells expressing GST-Pi rather than up-regulation of
GST-Pi expression. These findings suggested that GST-Pi bio-
logical action may contribute to tumor cell survival and to
MDR phenotype and may be correlated with the clinical
course of the disease. Moreover, we may speculate that
patients in the CR group who have high GST-Pi expression
are more likely to relapse.
GST-Pi may participate in MDR development by acting
two distinct roles. Firstly, GST-Pi may cause enzyme-
mediated detoxification of lipid peroxidation products. Since
anthracyclines are likely to cause peroxidation of membrane
lipids, increased GST-Pi levels could contribute to protection
from toxicity caused by these agents.15 Secondly, GST-Pi plays
a key role in regulating the MAP kinase pathway via inhibiting
jun N-terminal kinase (JNK). In cells that are not stressed,
JNK activity is low due to its sequestration in a GST-Pi:
JNK complex. However, suppression of JNK activity is
reversed by conditions of oxidative stress resulting in the disso-
ciation of the GST-Pi:JNK complex and induction of apopto-
sis. Elevated expression of GST-Pi can alter the balance of
regulation of kinase pathways during drug treatment, protect-
ing cells from death or apoptosis.16
As for impact of GST-Pi expression on patients’ prognosis,
our study demonstrated that patients with positive GST-Pi
expression had a statistically significant shorter mean overall
survival (OS) time (15.0 months) than those with negative
GST-Pi expression (34.5 months), with a relative risk of death
in GST-Pi positive patients being 7.25-fold that of GST-Pi neg-
ative patients. As for Disease-free survival (DFS), after treat-
ment, patients with positive GST-Pi expression had
statistically significant shorter mean DFS time (13.09 months)
than those with negative GST-Pi expression (28.56 months),eters in all studied groups.
WBCs count Blast cells %
r= 0.583, P= 0.038 r= 0.612, P = 0.030
r= 0.612, P= 0.030 r= 0.667, P = 0.018
thacin r= 0.667, P= 0.018 r= 0.667, P = 0.018
r= 0.612, P= 0.030
258 S.A. Ebeed et al.with a relative risk of relapse in GST-Pi positive patients being
4.23-fold that of GST-Pi negative patients. Thus, GST-Pi
expression at diagnosis may be an important prognostic mar-
ker for patients’ survival. These results are in agreement with
Gilbert et al.,17 who found that increased GST-Pi expression
is a predictor of early death in breast cancer patients.
MRP-1, a member of the ATP-binding cassette superfam-
ily, acts as drug efflux pump whose over-expression is an
important cause of treatment failure in AML.18 While some
studies confirm MRP-1’s lack of prognostic utility,19,20 others
have shown that MRP-1 detection is predictive of outcome,
and adds prognostic value to P-gp for both CR rates,
relapse-free, and OS for patients expressing both phenotypes.21
These inconsistencies may be due to different populations,
population sizes or methodological differences.
Our results showed that the percent positivity of MRP-1
expression in AML patients before treatment was very low
and not significantly different from that in the control group.
We could attribute the low percent positivity to heterogeneity
of MRP-1 expression among AML patients with different
FAB subgroups and cytogenetic abnormalities, or due to its
deletion in specific cytogenetic karyotypes.22 Our results were
consistent with other studies that found that mRNA levels of
MRP-1 were equally expressed in healthy donors and AML
patients.12,19,20,22
In CR group, MRP-1 expression at presentation was not
significantly different from its expression after achieving CR.
Our results were confirmed by studies of Schaich et al.23 and
Filipits et al.20 who found that MRP-1 expression had no value
in predicting response to induction chemotherapy and no
effect on remission rate.
In UR group, MRP-1 expression at presentation was not
significantly different from that after induction cycle, which
confirms the findings of Van der Kolk et al.22 who observed
no consistent up-regulation of MRP-1 mRNA expression in
relapsed versus de novo AML cells. On the contrary, Mah-
joubi et al.,21 found that high MRP-1 expression was associ-
ated with poor clinical outcome.
As for survival, no statistically significant difference in
mean DFS or OS time was found between patients with posi-
tive and negative MRP-1 expression. That was consistent with
Filipits et al.19 and Lohri et al.12, who reported that MRP-1
expression had no impact on OS or DFS and had no prognos-
tic value.
In CR group, there was a significant positive correlation
between MRP-1 expression and WBCs count at presentation
which could be attributed to its production by leukocytes.
These results were in accordance with Schaich et al.23 who
found an association between higher MRP-1 expression and
WBC counts >100  109/l.
Our results also showed that there was no significant corre-
lation between GST-Pi and MRP-1. This may be due to low
level of MRP-1 expression. Do et al.24 and Moureau-
Zabotto et al.25 also observed no significant correlation
between mRNA expression of GST-Pi and MRP-1, which
agrees with the present study.4.2. Modulation of multidrug resistance
MDR renders chemotherapy ineffective, and if high doses of
drugs are used to overcome resistance, toxic effects appear.MDR could be modulated through modulation of agents
implicated in resistance. Modulation can be done by using a
relatively non-toxic agent, in combination with an anti-
cancer drug, in order to improve therapeutic efficacy by dis-
turbing drug resistance mechanisms.26
The data fore mentioned suggest that GST-Pi may play a
role in MDR in AML patients, while MRP-1 is not expected
to have a significant role in the process. Thus, to reverse
MDR, indomethacin, an inhibitor of GST-Pi isoenzyme, was
used along with the chemotherapy regimen for a 2nd cycle in
UR patients.27
After the 2nd cycle in combination with indomethacin the
GST-Pi percent positivity significantly decreased (from 80%
to 20%), probably due to the inhibitory effect of indomethacin
on GST-Pi expression. The decrease in GST-Pi expression is
expected to enhance cell death or apoptosis. Our results con-
firmed those of Draper et al.,28 and Song et al.,27 who found
that the drug-sensitizing effect of indomethacin was dependent
on direct inhibition of GST and activation of a chemothera-
peutic drug-induced apoptotic pathway.
The present study showed that, patients taking 2nd cycle
chemotherapy in combination with indomethacin had signifi-
cantly longer mean OS time (31.0 months) than patients taking
chemotherapy alone (18.87 months). The relative risk of death
in patients taking chemotherapy alone was 4.25-fold that of
patients treated by chemotherapy combined with indometha-
cin. That indicates that combination of indomethacin with
chemotherapy could improve survival and reverse MDR phe-
notype in AML patients.
As for MRP-1, the change in percent positivity of MRP-1
after the 2nd cycle combined with indomethacin was not sig-
nificant. Matsunaga et al.29 findings were contradictory to
our results, as he found that indomethacin was a sensitizer in
doxorubicin resistant leukemia cells, which decreased expres-
sion of MRP-1 by inhibiting MRP-1 promoter activity. But
our results did not support such inhibition due to the very
low initial positivity of MRP-1 in our patients group.
In conclusion, GST-Pi may have a role in MDR phenotype
in AML patients, but not MRP-1. Furthermore, GST-Pi inhi-
bition by indomethacin significantly reduced MDR in AML
patients and improved survival.Conflict of interest
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